Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion type Assertion NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_head.
- NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion description "[The data suggest that the ability of sorafenib to activate GSK-3? and alter the intracellular distribution of p53 may be exploitable as an adjunct to agents that prevent the HDM2-dependent degradation of p53 in the treatment of melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_provenance.
- NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion evidence source_evidence_literature NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_provenance.
- NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion SIO_000772 21929745 NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_provenance.
- NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion wasDerivedFrom befree-2016 NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_provenance.
- NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_assertion wasGeneratedBy ECO_0000203 NP924708.RA3a-5ysdIHpjXBCNVTwXAQDYgzps_iZ8_iNgJxXdTQI0130_provenance.